Clinical Outcomes and Longitudinal Circulating Tumor DNA Changes After Treatment With Nivolumab and Olaparib in Immunotherapy Relapsed Melanoma With Detected Homologous Recombination Deficiency

Cold Spring Harbor Molecular Case Studies Manuscript
Authors Karam Khaddour, Michael Ansstas, and George Ansstas

The treatment of immunotherapy relapsed cutaneous melanoma constitutes a challenge in both research and clinical practice fields given the lack of effective therapeutic options. Homologous recombination deficiency (HRD) has been identified in several solid cancers including cutaneous melanoma. However, the utility of medications targeting HRD cancer cells is an uncharted territory in melanoma. Moreover, preclinical evidence suggests a synergistic role of combining immune checkpoint blockade (ICB) with drugs targeting HRD cancer cells such as PARP inhibitors. Here, we present a case study of a patient with immunotherapy relapsed melanoma who was found to have detected HRD and was treated with nivolumab (ICB) and olaparib (PARP inhibitors).